A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
- Conditions
- AsthmaChronic BronchitisChronic Obstructive Pulmonary Disease (COPD)Emphysema
- Interventions
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 306
- Registration Number
- NCT01302587
- Locations
- 🇺🇸
Teva Clinical Study Site 10099, Seattle, Washington, United States
🇺🇸Teva Clinical Study Site 10090, Indianapolis, Indiana, United States
🇺🇸Teva Clinical Study Site 10097, Overland Park, Kansas, United States
A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives
- Conditions
- Follicle DevelopmentFollicle CountOvarian FollicleFollicle SizeOral Contraceptive
- Interventions
- Drug: 28-day drospirenone oral contraceptive
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT01291004
- Locations
- 🇺🇸
Teva Investigational Site 10119, Philadelphia, Pennsylvania, United States
🇺🇸Teva Investigational Site 10118, Seattle, Washington, United States
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1052
- Registration Number
- NCT01290887
- Locations
- 🇺🇸
Teva Investigational Site 53, Clearwater, Florida, United States
🇺🇸Teva Investigational Site 19, Tallahassee, Florida, United States
🇺🇸Teva Investigational Site 46, Bangor, Maine, United States
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 489
- Registration Number
- NCT01287039
- Locations
- 🇺🇸
Teva Investigational Site 61, Los Angeles, California, United States
🇺🇸Teva Investigational Site 51, Boston, Massachusetts, United States
🇵🇱Teva Investigational Site 500, Ostrow Wielkopolski, Poland
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 464
- Registration Number
- NCT01285323
- Locations
- 🇩🇪
Teva Investigational Site 361, Berlin, Germany
🇬🇷Teva Investigational Site 382, Heraklion, Crete, Greece
🇺🇸Teva Investigational Site 69, El Paso, Texas, United States
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 315
- Registration Number
- NCT01270464
- Locations
- 🇺🇸
Teva Investigational Site 16, Fort Worth, Texas, United States
🇦🇷Teva Investigational Site 127, Ciudad Autonoma de Buenos Aire, Argentina
🇦🇷Teva Investigational Site 123, Rosario-Santa Fe, Argentina
Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 391
- Registration Number
- NCT01240863
- Locations
- 🇺🇸
DCT-Sugarland, LLC, Sugar Land, Texas, United States
🇺🇸Georgia Institute for Clinical Research, LLC, Marietta, Georgia, United States
🇺🇸KRK Medical Research, Dallas, Texas, United States
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT01223365
- Locations
- 🇺🇸
Physician Alliance Research Center, Anaheim, California, United States
🇺🇸South Orange County Surgical Medical Group, Laguna Hills, California, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 331
- Registration Number
- NCT01218009
- Locations
- 🇺🇸
Teva Clinical Study Site, Greenfield, Wisconsin, United States
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
- Conditions
- DLBCL
- Interventions
- Biological: TL011Biological: Rituximab
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT01205737
- Locations
- 🇧🇬
Teva Investigational Site 59003, Plovdiv, Bulgaria
🇧🇬Teva Investigational Site 59002, Sofia, Bulgaria
🇧🇬Teva Investigational Site 59001, Sofia, Bulgaria